Efficacy and safety of pembrolizumab and axitinib as first-line treatment for patients with advanced renal cell carcinoma: Real-world experience in Japan.
Ken-Ichi HaradaRyo SatoYukari BandoAsuka SanoYuto MatsushitaKeita TamuraTomoaki TerakawaJunya FurukawaNaohiro FujimotoMasato FujisawaHideaki MiyakePublished in: International journal of urology : official journal of the Japanese Urological Association (2023)
To our knowledge, this is the first study focusing on real-world outcomes following pembrolizumab and axitinib for treatment-naïve advanced Japanese RCC patients, which showed the efficacy and safety of this combined therapy being similar or even superior to those in clinical trial.
Keyphrases
- renal cell carcinoma
- clinical trial
- end stage renal disease
- chronic kidney disease
- ejection fraction
- advanced non small cell lung cancer
- newly diagnosed
- peritoneal dialysis
- randomized controlled trial
- stem cells
- patient reported outcomes
- open label
- metastatic renal cell carcinoma
- phase ii
- mesenchymal stem cells
- tyrosine kinase
- phase iii